跳至主要内容
临床试验/NCT06157580
NCT06157580已完成早期 1 期

Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

Anna Stanhewicz, PhD1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2023年12月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
Change in microvascular angiotensin II (ang II) type 2 receptor (AT2R)-mediated dilation response measured by laser-Doppler flowmetry

研究概览

简要总结

Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.

The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function.

In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • women who had preeclampsia and women who did not have preeclampsia
  • 12 weeks to 5 years postpartum
  • 18-45 years old

排除标准

  • history of hypertension or metabolic disease before pregnancy
  • history of gestational diabetes or gestational hypertension
  • skin diseases
  • current tobacco use
  • current antihypertensive medication
  • statin or other cholesterol-lowering medication
  • currently pregnant or planning to become pregnant
  • body mass index less than <18.5 or >30 kg/m2
  • allergy to materials used during the experiment.(e.g. latex),
  • known allergy to study drugs

研究组 & 干预措施

History of a preeclampsia

Other

Women who had preeclampsia in their most recent pregnancy

干预措施: Compound 21 (Drug)

History of a preeclampsia

Other

Women who had preeclampsia in their most recent pregnancy

干预措施: Angiotensin II (Drug)

History of a healthy pregnancy

Other

Women who had an uncomplicated pregnancy

干预措施: Compound 21 (Drug)

History of a healthy pregnancy

Other

Women who had an uncomplicated pregnancy

干预措施: Angiotensin II (Drug)

结局指标

主要结局

Change in microvascular angiotensin II (ang II) type 2 receptor (AT2R)-mediated dilation response measured by laser-Doppler flowmetry

时间窗: at the study visit, an average of 4 hours

cutaneous vascular vasodilator responses to compound 21 perfusion in lactated Ringer's and losartan treated microdialysis sites

Change in microvascular ang II-mediated constriction response measured by laser-Doppler flowmetry

时间窗: at the study visit, an average of 4 hours

cutaneous vascular vasoconstrictor responses to angiotensin II perfusion in lactated Ringer's and PD-123319 treated microdialysis sites

次要结局

未报告次要终点

研究者

发起方
Anna Stanhewicz, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Anna Stanhewicz, PhD

Assistant Professor

University of Iowa

研究点 (1)

Loading locations...

相似试验